文献速递睡眠呼吸障碍肺栓塞与肺血管病

持续气道正压治疗对阻塞性睡眠呼吸暂停或肥胖低通气综合征患者肺动脉压力的影响:系统综述与荟萃分析

Impact of positive airway pressure therapy on pulmonary arterial pressures in obstructive sleep apnoea or obesity hypoventilation syndrome: a systematic review and meta-analysis.
PubMed 文献 · Eur Respir J · 2026-04-02

该系统综述与荟萃分析纳入23项研究共733例患者,评估PAP治疗对OSA或OHS患者肺动脉压力的影响。结果显示PAP治疗使肺动脉压力平均降低5.96 mmHg(95%CI 3.20-8.73),基线存在肺动脉高压者降低11.41 mmHg(95%CI 8.66-14.15),OSA与OHS获益相似,但证据确定性低。

要点

  • PAP治疗可降低以重度OSA或OHS为主患者的肺动脉压力,基线有肺动脉高压者降幅更明显。
  • OSA与OHS患者获益相似,未见性别差异,但研究间异质性高(I2>85%)。
  • 证据确定性低,结果可能不适用于轻度OSA患者,临床需谨慎应用。

核心结论

  • PAP治疗可降低以重度OSA或OHS为主患者的肺动脉压力,基线存在肺动脉高压者降幅更显著。
  • 因证据确定性低,结果在临床实践中需谨慎应用,且可能不适用于轻度OSA患者。

研究设计与样本

  • 系统综述与随机效应荟萃分析(PROSPERO注册号CRD42024595312),遵循PRISMA指南。
  • 检索PubMed、Embase、Scopus、Web of Science、EBSCO、Cochrane CENTRAL及ClinicalTrials.gov。
  • 纳入23项研究(20项观察性研究、3项随机对照试验),共733例患者;其中OSA 19项(n=518),OHS合并OSA 4项(n=215)。
  • 多数患者为重度OSA;主要结局为PAP治疗前后肺动脉压力变化,分别分析肺动脉收缩压与平均肺动脉压。

主要发现

  • PAP治疗与肺动脉压力平均降低5.96 mmHg相关(95%CI 3.20-8.73;p<0.0001)。
  • 基线存在肺动脉高压的患者(n=233)肺动脉压力降低11.41 mmHg(95%CI 8.66-14.15;p<0.00001)。
  • PAP治疗的有益效应在OSA与OHS患者中相似,且未见性别差异。
  • 研究间异质性高(I2>85%),反映研究设计、人群和方法学差异。

临床怎么用

  • 对以重度OSA或OHS为主且合并肺动脉高压的患者,PAP治疗可能有助于降低肺动脉压力。
  • 因证据确定性低,临床决策需结合个体情况谨慎评估,不应将结果外推至轻度OSA患者。

局限性

  • 纳入研究以观察性研究为主,随机对照试验仅3项。
  • 研究间异质性高(I2>85%),与设计、人群和方法学差异有关。
  • 证据确定性低,结果可能不适用于轻度OSA患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited and conflicting evidence on the impact of obstructive sleep apnoea (OSA) and its treatment with positive airway pressure (PAP) therapy on pulmonary hypertension (PH). Our research question was: does treatment of OSA and obesity hypoventilation syndrome (OHS) with PAP therapy improve pulmonary arterial pressures? METHODS: A systematic review and random effects meta-analysis was performed (PROSPERO: CRD42024595312). PubMed, Embase, Scopus, Web of Science, EBSCO, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov were searched using the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Studies reporting pulmonary arterial pressure in patients with OSA and OHS pre- and post-PAP therapy were included. The primary outcome was post-PAP therapy change in pulmonary arterial pressures, with separate analyses on pulmonary arterial systolic pressure and mean pulmonary arterial pressure. Sensitivity analysis was performed to assess the impact of PAP therapy in patients with only OSA or OHS. RESULTS: 23 studies (20 observational and three randomised controlled trials) with 733 patients were included (19 with OSA (n=518) and four with OHS and concomitant OSA (n=215)). Most patients had severe OSA. PAP therapy was associated with a mean reduction in pulmonary arterial pressure of 5.96 (95% CI 3.20-8.73) mmHg; p<0.0001. In patients with baseline PH (n=233), the reduction was 11.41 (95% CI 8.66-14.15) mmHg; p<0.00001. The beneficial effect of PAP therapy was similar in OSA and OHS. There was no sex difference in the impact of PAP therapy. Heterogeneity was high across studies (I2>85%), reflecting differences in study design, patient populations and methodologies. CONCLUSIONS: PAP therapy reduces pulmonary arterial pressures in patients with mostly severe OSA or OHS, with a more pronounced effect in those with baseline PH. As such, our findings may not apply to patients with milder degrees of OSA. While reductions in pulmonary arterial pressures were observed in all groups, the low certainty necessitates cautious application of these findings in clinical practice.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Mokhlesi B, Hache-Marliere M, Bjork ST, et al. Impact of positive airway pressure therapy on pulmonary arterial pressures in obstructive sleep apnoea or obesity hypoventilation syndrome: a systematic review and meta-analysis. Eur Respir J. 2026. PMID: 41309270. doi:10.1183/13993003.01037-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。